Gemtuzumab Ozogamicin treatment represents a unique breakthrough in the management of severe blood disease, mainly severe leukemic leukemia (AML). This particular conjugate pairs a engineered immunoglobulin specific https://www.targetmol.com/compound/gemtuzumab